|
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PTEN, an important negative regulator of the PI3K-Akt pathway, is also commonly mutated in glioma, leading to constitutive activation of Akt.
|
19549905 |
2009 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sevoflurane downregulates insulin-like growth factor-1 to inhibit cell proliferation, invasion and trigger apoptosis in glioma through the PI3K/AKT signaling pathway.
|
31305291 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis.
|
16170333 |
2005 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the many possible mechanisms underlying its pathogenesis, hyperactivation of the PI3K/Akt pathway is essential to the occurrence and development of glioma through the loss of PTEN or somatic activating mutations in PIK3CA.
|
30542720 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the role of different PI3K isoforms in glioma is still largely unclear.
|
22079609 |
2012 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
|
28423515 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI-3-K stimulation seems to be critical for CD95 receptor signalling since, first, inhibition of PI-3-K prevents CD95-mediated apoptosis and, second, CD95 receptor ligation fails to induce tyrosine phosphorylation or activation of PI-3-K in CD95-resistant glioma cells.
|
9446703 |
1998 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, KEGG PathwayFinder by gene correlation analysis was performed on the R2: Genomics Analysis and Visualization Platform, which revealed a high association between Ngb and the phosphatidylinositol 3‑kinase (PI3K)/AKT pathway using glioma data (GSE4290) from the Gene Expression Omnibus database.
|
29207186 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this study was therefore to identify magnetic resonance spectroscopy (MRS)-detectable metabolic biomarkers associated with IDHmut glioma response to the dual PI3K/(mTOR) inhibitor XL765.
|
31324855 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, the present study was conducted with aims of exploring the ability of MCL1 silencing to influence glioma cell senescence and apoptosis through the mediation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway.
|
30296359 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K-AKT-mTOR signaling is a valuable treatment target for human glioma.
|
29228741 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CEP55 promotes cell proliferation and inhibits apoptosis via the PI3K/Akt/p21 signaling pathway in human glioma U251 cells.
|
29552118 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that the PTEN-PI3K axis regulates HIF1α in glioma models.
|
24162827 |
2014 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we generated a patient-derived glioma sphere-forming cell (GSC) xenograft model resistant to the PI3K-specific inhibitor BKM-120.
|
31416846 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, our results suggest that miR-93 might play an important role in glioma progression and uncover a novel mechanism for constitutive PI3K/Akt activation in gliomas.
|
25823655 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma.
|
29774498 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature.
|
28881745 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings shed new light on the miR-223/PAX6 pathway in glioma and this pathway might modulate the sensitivity of glioma to TMZ via regulating PI3K/Akt signaling pathway..
|
28332226 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that combined inhibition of MEK and PI3K/mTOR is a rational strategy for the treatment of high-grade gliomas and may be an effective adjuvant therapy for this disease.
|
21057530 |
2011 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanistic investigation showed that LINC01426 exhibited its tumor promoter role by modulating PI3K/Akt signaling pathway in glioma.
|
30338804 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that the PI3K/AKT signaling pathway regulates glioma cell proliferation, in part via repression of the Wnt/β-catenin pathway.
|
20888802 |
2010 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evodiamine activates cellular apoptosis through suppressing PI3K/AKT and activating MAPK in glioma.
|
29535541 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inhibitory effect of miR-219-5p on MAPK and PI3K pathways and glioma cell migration could be rescued by the overexpression of wild type EGFR and vIII mutant of EGFR (both lacking 3'-UTR and thus being insensitive to miR-219-5p) suggesting that the inhibitory effects of miR-219-5p were indeed because of its ability to target EGFR.
|
23690991 |
2013 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To address the importance of PI3K blockade, we showed in PTEN(mt) glioma that combining PI-103 and erlotinib was superior to either monotherapy or to therapy combining erlotinib with either rapamycin (an inhibitor of mTOR) or PIK-90 (an inhibitor of PI3Kalpha).
|
17804702 |
2007 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similar to PI3K, NF-κB is associated with the regulation of BMSCs migration toward glioma.
|
26034878 |
2015 |